Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.790
+0.040 (1.07%)
At close: Oct 26, 2026, 4:00 PM EDT
3.840
+0.050 (1.32%)
Pre-market: Oct 27, 2026, 4:43 AM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.18. The average 1-year stock price forecast is 168.60% higher than the current stock price, while the lowest is $4.00 (+5.54%) and the highest is $16 (+322.16%).
Price Target: $10.18 (+168.60%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 10 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $11 | Buy | Maintains | $11 | +190.24% | Oct 19, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $13 | Buy | Maintains | $13 | +243.01% | Oct 1, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Initiates $10 | Buy | Initiates | $10 | +163.85% | Sep 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +322.16% | Aug 10, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $10 | Buy | Maintains | $10 | +163.85% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
6.18M
from 7.83M
Decreased by -21.03%
Revenue Next Year
5.34M
from 6.18M
Decreased by -13.63%
EPS This Year
-0.65
from -0.53
EPS Next Year
-0.78
from -0.65
EPS and Forward PE are based on non-GAAP adjusted numbers.